Interferon-γ Treatment of Human Laryngotracheal Stenosis–Derived Fibroblasts | Zendy

Kevin Motz | Zendy; Idris Samad | Zendy; Linda X. Yin | Zendy; Michael K. Murphy | Zendy; Madhavi Duvvuri | Zendy; Dacheng Ding | Zendy; Alexander T. Hillel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interferon-γ Treatment of Human Laryngotracheal Stenosis–Derived Fibroblasts

Author(s) -

Kevin Motz,

Idris Samad,

Linda X. Yin,

Michael K. Murphy,

Madhavi Duvvuri,

Dacheng Ding,

Alexander T. Hillel

Publication year - 2017

Publication title -

jama otolaryngology–head and neck surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.571

H-Index - 128

eISSN - 2168-619X

pISSN - 2168-6181

DOI - 10.1001/jamaoto.2017.0977

Subject(s) - laryngotracheal stenosis , fibrosis , fibroblast , medicine , pathology , interferon , extracellular matrix , subglottis , cytokine , in vitro , stenosis , tracheal stenosis , larynx , immunology , biology , anatomy , glottis , biochemistry , microbiology and biotechnology

Laryngotracheal stenosis (LTS) is a fibroproliferative disorder of the glottis, subglottis, and trachea. In models of fibrosis from other organ systems, the CD4+ T-cell response has been shown to regulate extracellular matrix deposition. Specifically, helper T cell 2 (TH2) promotes fibrosis, whereas TH1 and associated cytokines have been shown to be antifibrotic. However, this antifibrotic effect of the TH1 response has not been demonstrated in LTS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research